Kuros Biosciences AG (KURN) Earnings Call Transcripts

Kuros Biosciences AG's Latest Earnings Call - June 17, 2026

In the second quarter of 2026, Kuros Biosciences AG reported a significant milestone by achieving profitability for the first time, with revenues reaching $146.1 million, up 72% year-over-year. The company highlighted its strong market position, moving from the #9 to #3 in biologics and #2 in fusion products within a year. Management maintained its guidance for fiscal year 2026, targeting adjusted EBITDA margins of 14% and revenue between $300 million and $330 million, signaling confidence in continued growth driven by new product launches and market expansion efforts.

Reported metrics

Guidance from management

Management maintained its guidance for 2026, targeting adjusted EBITDA margins of 14% and revenue between $300 million and $330 million, indicating confidence in growth from new product launches and market expansions.

What management said

Okay. Welcome back. So you've heard the high-level strategy from the Kuros leadership team. Next up, we will invite Mr. Golberg, who is going to give us that deep dive into foot and ankle, talk through the procedures that he does and how MagnetOs has impacted his practice, and then we'll end this session with our patient video from Alison. Over to you, Mr. Golberg.

Thank you, Daniel. I will now ask all of our hosts to come up to the front for our Q&A session. We will start with Q&A in the room, and then we'll move to online where Alex will be fielding questions. Over to you, Daniel. I'll let you pick the respondents.

What analysts pressed on

Analysts expressed concerns about the slower-than-expected commercial scaling despite strong product performance. Questions were raised regarding potential barriers such as adoption rates, pricing, and reimbursement challenges in the U.S. market.

Main topics on the call

• Achieving Profitability — Kuros achieved profitability for the first time, a significant milestone for a medical device company. CEO Christopher Fair stated, "last year, we went to $146.1 million in revenue in U.S. dollars, 72% total growth and a...
• Market Share Growth — The company has rapidly improved its market share in biologics, moving from #9 to #3 and from #2 to #1 in fusion products. Fair noted, "we are continuously taking market share... and moving from a #9 to a #3 position."
• Expansion into New Markets — Kuros is expanding into the trauma and foot and ankle markets, with significant opportunities identified. Fair emphasized the potential, stating, "we're just getting started" in these new areas.
• Clinical Evidence and Trials — Kuros is investing heavily in Level 1 clinical studies to support its products, which sets it apart from competitors. Joost de Bruijn highlighted, "we are only one of the very few synthetics that have done Level 1 studie...

Read the full Kuros Biosciences AG transcript (June 17, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Kuros Biosciences AG earnings call transcripts on record, spanning August 15, 2024 to June 17, 2026. Based on this history, Kuros Biosciences AG reports semi-annually. The most recent call on file is dated June 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

KURN

Exchange

SWX

Country

CH

Sector

Health Care

Industry

Biotechnology

Calls on record

6

First call

August 15, 2024

Most recent

June 17, 2026

Reporting cadence

semi-annually